- Home
- DGICA vs ACRS Comparison
DGICA vs ACRS Comparison
Compare DGICA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DGICA | ACRS |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | United States |
| Employees | 851 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 607.2M | 608.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | DGICA | ACRS |
|---|---|---|
| Price | $17.41 | $4.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $19.00 | $10.20 |
| AVG Volume (30 Days) | 97.8K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.14% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | $7.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.11 | $1.34 |
| 52 Week High | $21.06 | $5.15 |
Technical Indicators
Market Signals| Indicator | DGICA | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 55.45 | 52.41 |
| Support Level | $16.43 | $4.13 |
| Resistance Level | $17.78 | $4.73 |
| Average True Range (ATR) | 0.37 | 0.27 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 77.61 | 61.20 |
Price Performance
Historical ComparisonAbout DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.